Trials / Completed
CompletedNCT02025608
Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Mauro Manconi · Academic / Other
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to explore whether patients with restless legs syndrome (RLS) differ from healthy subjects in daytime and night time autonomic function and cardiovascular risk markers and whether 4 week treatment with pramipexole affects autonomic function and cardiovascular risk markers in patients with RLS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pramipexole | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2016-12-31
- Completion
- 2016-12-31
- First posted
- 2014-01-01
- Last updated
- 2017-01-24
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02025608. Inclusion in this directory is not an endorsement.